Atara Biotherapeutics (ATRA) Receives a Buy from William Blair


William Blair analyst Matt Phipps reiterated a Buy rating on Atara Biotherapeutics (ATRA) on December 10. The company’s shares opened today at $42.68.

Phipps observed:

“We look forward to additional details on these patients and the treatment outcomes with tabelecleucel to be presented at the conference on December 15. Although this is a rare tumor , representing roughly 10% to 20% of soft tissue sarcomas, patients diagnosed with metastatic disease have limited treatment options and poor prognosis. Overall, we are encouraged by the initial clinical activity of tabelecleucel in a second solid tumor indication (first being nasopharyngeal carcinoma) and look forward to additional updates on a potential clinical development pathway . The results from the abstract are summarized in exhibit 1.”

According to TipRanks.com, Phipps is ranked #3770 out of 5108 analysts.

Currently, the analyst consensus on Atara Biotherapeutics is a Moderate Buy with an average price target of $44, which is a 3.1% upside from current levels. In a report issued on November 29, Cowen & Co. also reiterated a Buy rating on the stock.

.

See today’s analyst top recommended stocks >>

Based on Atara Biotherapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $58.36 million. In comparison, last year the company had a GAAP net loss of $31.1 million.

Based on the recent corporate insider activity of 94 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Atara Biotherapeutics, Inc. operates as a clinical stage company which focuses on developing novel therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. Its product candidates are biologics targeting myostatin and activin, members of the transforming growth factor-beta, protein superfamily, which play roles in the growth and maintenance of muscle and many other body tissues. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.